Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma

被引:128
作者
Zhao, Xiaohui [1 ,2 ]
Liu, Yimin [1 ,2 ]
Li, Zhihua [2 ,3 ]
Zheng, Shangyou [2 ,4 ]
Wang, Zairui [5 ]
Li, Wenzhu [2 ]
Bi, Zhuofei [1 ,2 ]
Li, Liting [1 ,2 ]
Jiang, Yanhui [1 ,2 ]
Luo, Yuming [2 ,4 ]
Lin, Qing [2 ,4 ]
Fu, Zhiqiang [2 ,4 ]
Chen Rufu [2 ,4 ]
机构
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Radiotherapy, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Key Lab Malignant Tumor Gene Regulat & Target The, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[4] Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou, Guangdong, Peoples R China
[5] Armed Police Corps Hosp Guangdong Prov, Dept Nephrol, Guangzhou, Guangdong, Peoples R China
关键词
Pancreatic ductal adenocarcinoma; Competing endogenous RNA; linc00511; hsa-miR-29b-3p; VEGFA; LONG-NONCODING-RNA; CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; GENE; PATHWAY; MIR-29; IDENTIFICATION; METASTASIS;
D O I
10.1111/jcmm.13351
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy. Long non-coding RNAs (lncRNAs) are important regulators in pathological processes, yet their potential roles in PDAC are poorly understood. Here, we identify a fundamental role for a novel lincRNA, linc00511, in the progression of PDAC. Linc00511 levels in PDAC tissue specimens and cell lines were examined by quantitative real-time PCR. Corresponding adjacent non-neoplastic tissues were used as controls. The function of linc00511 in PDAC cell lines was determined by RNA interference approach invitro and invivo. Fluorescence insitu hybridization (FISH) was used to characterize linc00511 expression in PDAC cells. Insights of the mechanism of competitive endogenous RNAs (ceRNAs) were obtained from bioinformatic analysis, luciferase assays and RIP assays. The association between the linc00511/hsa-miR29b-3p axis and VEGFA was verified by Western blotting assay. Immunohistochemistry was performed to evaluate the expression of VEGFA in PDAC samples. The aberrant up-regulation of linc00511 was detected in PDAC cell lines and patient specimens compared with controls. An increase in linc00511 expression indicates the adverse clinical pathological characteristics and poor prognosis. Functionally, linc00511 depletion in PDAC cells decreased proliferation, migration, invasion and endothelial tube formation. Mechanistically, linc00511 could up-regulate VEGFA via its competing endogenous RNA (ceRNA) activity on hsa-miR-29b-3p. In summary, our results define an important axis controlling proliferation, invasion and tumour angiogenesis in PDAC. Linc00511 is a novel lncRNA that plays a significant regulatory role in the pathogenesis and progression of PDAC. Thus, Linc00511 represents a new prognostic biomarker to predict clinical outcome of PDAC patients after surgery and may serve as a potential therapeutic target for PDAC treatment.
引用
收藏
页码:655 / 667
页数:13
相关论文
共 59 条
  • [1] [Anonymous], SCIENTIFICWORLDJOURN
  • [2] Competing Endogenous RNA and Interactome Bioinformatic Analyses on Human Telomerase
    Arancio, Walter
    Pizzolanti, Giuseppe
    Genovese, Swonild Ilenia
    Baiamonte, Concetta
    Giordano, Carla
    [J]. REJUVENATION RESEARCH, 2014, 17 (02) : 161 - 167
  • [3] Long Noncoding RNAs: Cellular Address Codes in Development and Disease
    Batista, Pedro J.
    Chang, Howard Y.
    [J]. CELL, 2013, 152 (06) : 1298 - 1307
  • [4] Origins and Mechanisms of miRNAs and siRNAs
    Carthew, Richard W.
    Sontheimer, Erik J.
    [J]. CELL, 2009, 136 (04) : 642 - 655
  • [5] GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression
    Chou, Jonathan
    Lin, Jeffrey H.
    Brenot, Audrey
    Kim, Jung-whan
    Provot, Sylvain
    Werb, Zena
    [J]. NATURE CELL BIOLOGY, 2013, 15 (02) : 201 - 213
  • [6] VEGF-A/VEGFR-2 Signaling Plays an Important Role for the Motility of Pancreas Cancer Cells
    Doi, Yosuke
    Yashiro, Masakazu
    Yamada, Nobuya
    Amano, Ryosuke
    Noda, Satoru
    Hirakawa, Kosei
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (08) : 2733 - 2743
  • [7] VEGF-targeted therapy: mechanisms of anti-tumour activity
    Ellis, Lee M.
    Hicklin, Daniel J.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (08) : 579 - 591
  • [8] Genetic association of gastric cancer with miRNA clusters including the cancer-related genes MIR29, MIR25, MIR93 and MIR106: Results from the EPIC-EURGAST study
    Espinosa-Parrilla, Yolanda
    Munoz, Xavier
    Bonet, Catalina
    Garcia, Nadia
    Vencesla, Adoracion
    Yiannakouris, Nikos
    Naccarati, Alessio
    Sieri, Sabina
    Panico, Salvatore
    Huerta, Jose M.
    Barricarte, Aurelio
    Menendez, Virginia
    Sanchez-Cantalejo, Emilio
    Dorronsoro, Miren
    Brennan, Paul
    Duarte-Salles, Talita
    Bueno-de-Mesquita, H. B.
    Weiderpass, Elisabete
    Lund, Eiliv
    Clavel-Chapelon, Francoise
    Boutron-Ruault, Marie-Christine
    Racine, Antoine
    Numans, Mattijs E.
    Tumino, Rosario
    Canzian, Federico
    Campa, Daniele
    Sund, Malin
    Johansson, Mattias
    Ohlsson, Bodil
    Lindkvist, Bjorn
    Overvad, Kim
    Tjonneland, Anne
    Palli, Domenico
    Travis, Ruth C.
    Khaw, Kay-Tee
    Wareham, Nick
    Boeing, Heiner
    Nesi, Gabriella
    Riboli, Elio
    Gonzalez, Carlos A.
    Sala, Nuria
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (09) : 2065 - 2076
  • [9] Long noncoding RNA XIST acts as an oncogene in non-small cell lung cancer by epigenetically repressing KLF2 expression
    Fang, Jing
    Sun, Cheng-Cao
    Gong, Cheng
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 478 (02) : 811 - 817
  • [10] Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer
    Feliu, J.
    Borrega, P.
    Leon, A.
    Lopez-Gomez, L.
    Lopez, M.
    Castro, J.
    Belda-Iniesta, C.
    Barriuso, J.
    Martinez, V.
    Gonzalez-Baron, M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (01) : 215 - 221